Dr. Martens plc (LON:DOCS - Get Free Report) rose 25.8% during trading on Thursday . The stock traded as high as GBX 76 ($1.03) and last traded at GBX 75.40 ($1.02). Approximately 8,364,149 shares were traded during mid-day trading, an increase of 271% from the average daily volume of 2,253,765 shares. The stock had previously closed at GBX 59.95 ($0.81).
Analysts Set New Price Targets
Separately, Royal Bank of Canada cut their price target on shares of Dr. Martens from GBX 7,000 ($94.75) to GBX 6,000 ($81.21) and set a "sector perform" rating for the company in a report on Monday, May 19th.
View Our Latest Report on Dr. Martens
Dr. Martens Stock Performance
The company has a market cap of £795.54 million, a PE ratio of 11.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The firm's fifty day moving average is GBX 55.34 and its 200 day moving average is GBX 62.91. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27.
Dr. Martens (LON:DOCS - Get Free Report) last issued its quarterly earnings results on Thursday, June 5th. The company reported GBX 2.40 ($0.03) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, research analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.
Dr. Martens Cuts Dividend
The firm also recently announced a dividend, which was paid on Tuesday, April 8th. Stockholders of record on Thursday, March 6th were issued a dividend of GBX 0.85 ($0.01) per share. This represents a dividend yield of 1.47%. The ex-dividend date was Thursday, March 6th. Dr. Martens's payout ratio is 42.53%.
Insider Transactions at Dr. Martens
In other Dr. Martens news, insider Giles Wilson bought 32,640 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average price of GBX 54 ($0.73) per share, with a total value of £17,625.60 ($23,857.07). Insiders acquired 33,206 shares of company stock valued at $1,792,771 over the last 90 days. 4.36% of the stock is currently owned by corporate insiders.
About Dr. Martens
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Stories
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
